CRON — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-06

• •the ongoing impact of investigations or proceedings by the Trade Levies Commissioner of the Israel Ministry of Economy and Industry or other Israeli governmental authorities concerning alleged dumping of medical cannabis imports from Canada into Israel (collectively, the “Anti-Dumping Matters”), in…

• •expectations related to any future plans to re-enter the U.S. market;

• •expectations regarding revenues, expenses, gross margins, Adjusted EBITDA (as defined below), profitability, cash flows, foreign currency effects, interest income and capital expenditures;

• •our liquidity, capital resources and future cash requirements, including the sufficiency of our cash and cash equivalents and short-term investments to fund our business operations, acquisitions, strategic investments, share repurchases and capital expenditures;

• In June 2026, the Trade Levies Commissioner of the Israel Ministry of Economy and Industry announced the opening of a new investigation into alleged dumping of medical cannabis imports from Canada. This announcement followed the 2024 investigation by the Commissioner, which did not result in the imp…

Text removed vs the prior filing · source: 10-Q · 2026-05-11

• •the ongoing impact of the public investigation into Canadian licensed producers of alleged dumping of medical cannabis imports from Canada into Israel by the Trade Levies Commissioner of the Israel Ministry of Economy and Industry (the “Anti-Dumping Investigation”) and the proposed anti-dumping dut…

• •expectations related to the impact of our decision to exit our U.S. hemp-derived cannabinoid product operations and any future plans to re-enter the U.S. market;

• •expectations regarding revenues, expenses, gross margins and capital expenditures;

• For the three months ended March 31, 2026, we reported consolidated net revenue of $45.2 million, representing an increase of $12.9 million from the three months ended March 31, 2025. The increase was primarily due to higher cannabis flower sales in Israel and other countries, which carry no excise …

• For the three months ended March 31, 2026, we reported inventory write-down of $0.7 million, representing an increase of $0.7 million from the three months ended March 31, 2025. The current year write-downs relate to unusable inventory that was scrapped in the period. There were no such write-downs …

Text added vs the prior filing · source: 10-Q · 2026-08-06

• The imposition of an anti-dumping duty or other import restriction on our imports into Israel could have a material adverse effect on our business, financial condition and results of operations.

• On January 18, 2024, the Company was notified that the Trade Levies Commissioner of the Israel Ministry of Economy and Industry initiated a public investigation of alleged dumping of medical cannabis imports from Canada into Israel, which ultimately did not result in an anti-dumping duty being impos…

• In June 2026, the Trade Levies Commissioner initiated a new investigation concerning alleged dumping of medical cannabis imports from Canada into Israel. On July 28, 2026, the Commissioner terminated that investigation on procedural grounds. The termination was not based on a substantive determinati…

• If an anti-dumping duty or any other import restriction is imposed on the Company’s imports, our ability to continue to import cannabis into Israel, the performance of our business in Israel, and our results of operations, financial condition, business and prospects could be materially and adversely…